BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 26, 2024
Finance

Public Equity Report: Palvella lands on NASDAQ via Pieris merger

Plus: Verastem’s follow-on and Hangzhou Jiuyuan’s IPO plans
BioCentury | May 31, 2024
Finance

Public Equity Report: Insmed, Merus raise combined $1B+ after readouts

Plus: PIPEs help Celcuity, Cargo advance clinical programs
BioCentury | Jan 12, 2023
Deals

Jan. 12 Quick Takes: Cambrian launches Isterian to advance fibrosis programs

Plus: Oramed’s oral insulin misses in diabetes and Tricida going bankrupt
BioCentury | Nov 8, 2022
Distillery Therapeutics

Lymophatic-absorbed multi-kinase inhibitor for myelofibrosis

BioCentury | Feb 17, 2022
Deals

Cambrian launches new subsidiary to develop mTOR inhibitors

Novartis deal gives Tornado Therapeutics assets for age-related diseases
BioCentury | Jan 21, 2022
Discovery & Translation

ToolGen’s gene editor for hemophilia A and B; plus Praxis, TellBio and more

BioCentury’s roundup of translational news
BioCentury | Dec 3, 2021
Distillery Therapeutics

MAPK6 inhibition to sensitize cancers to mTOR inhibitors

BioCentury | Nov 24, 2021
Product Development

Nov. 23 Quick Takes: Aadi’s Fyarro approved for rare sarcoma

Plus BMS’s Zeposia, LoQus23’s seed round, Simcere’s COVID antiviral and more
BioCentury | Oct 8, 2021
Product Development

Diadem’s prognostic Alzheimer’s blood test bets on p53 biology

The Italian company plans to launch its test as a screening tool late this year
Items per page:
1 - 10 of 420
Help Center
Username
Request a Demo
Request Training
Ask a Question